(Q43817800)

27 November 2017

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion (English)

1 reference

27 November 2017

0 references

1 reference

Neben K

1

1 reference

27 November 2017

Moehler T

2

1 reference

27 November 2017

Kraemer A

3

1 reference

27 November 2017

Benner A

4

1 reference

27 November 2017

Egerer G

5

1 reference

27 November 2017

Ho AD

6

1 reference

27 November 2017

Goldschmidt H

7

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

British Journal of Haematology

27 November 2017

1 reference

27 November 2017

115

1 reference

27 November 2017

605-608

1 reference

27 November 2017

3

1 reference

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

27 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03142.X

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03142.X

Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03142.X

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03142.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03142.X

10.1046/J.1365-2141.2001.03142.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference